XFOR
BEARISHAt a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
AI-powered fundamental assessment
Key Strengths
Key Risks
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Ref P/E N/A, P/S 11.08
- Low Debt/Equity (0.41)
- P/S ratio of 11.08 is high for current earnings profile
- No Graham Number due to lack of earnings
Ref Growth rates and Analyst Targets
- 79% YoY Revenue growth
- Analyst target price of $11.67 suggests 172% upside
- Forward P/E remains negative (-4.44)
Ref Historical price trends
- Recent 6-month recovery
- 5-year return of -98.4%
- Consistent history of EPS misses in early 2020s
Ref Piotroski F-Score
- Current Ratio 10.16 indicates ample cash for short-term obligations
- Piotroski F-Score 0/9 is the lowest possible health rating
- ROE of -75.99%
Ref Yield N/A
- No dividend paid
- No capacity for dividends given current losses
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for XFOR and closest competitors.
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
XFOR
X4 Pharmaceuticals, Inc.
Primary
|
-98.4% | -90.0% | -29.0% | +38.5% | +12.0% | +3.4% |
|
NRC
National Research Corporation
Peer
|
-58.9% | -57.9% | +63.5% | +50.6% | -1.2% | 0.0% |
|
AKBA
Akebia Therapeutics, Inc.
Peer
|
-59.4% | +113.8% | -13.6% | -50.5% | -5.8% | +15.0% |
|
IRD
Opus Genetics, Inc.
Peer
|
+2.3% | -0.9% | +654.9% | +173.5% | +7.0% | +17.8% |
|
SRTA
Strata Critical Medical, Inc.
Peer
|
-54.4% | +64.4% | +74.4% | -8.4% | +6.0% | +13.1% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability
Profit margins and return metrics
Growth
Revenue and earnings growth rates
Financial Health
Balance sheet strength and liquidity metrics
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Quarterly Earnings History
EPS performance vs analyst estimates
Healthcare Sector Comparison
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
XFOR
X4 Pharmaceuticals, Inc.
|
BEARISH | $389.14M | - | -76.0% | -225.6% | $4.28 | |
|
NRC
National Research Corporation
|
BEARISH | $387.6M | 34.08 | 51.2% | 8.4% | $17.04 | Compare |
|
AKBA
Akebia Therapeutics, Inc.
|
BEARISH | $391.1M | - | -% | -2.3% | $1.46 | Compare |
|
IRD
Opus Genetics, Inc.
|
BEARISH | $381.36M | - | -242.4% | -% | $5.36 | Compare |
|
SRTA
Strata Critical Medical, Inc.
|
BEARISH | $397.54M | - | -8.0% | 21.0% | $4.57 | Compare |
SEC Filings
Recent regulatory filings from the SEC EDGAR database
XFOR's 10-Q filing dated November 5, 2025, provides no new financial highlights in the provided excerpt. The company reports no material changes to the risk factors previously disclosed in its June 30, 2025, report, noting that existing risks could adversely affect its financial condition, liquidity, and security prices.
Wall Street Analysts
Professional analyst ratings and price targets
Past News Coverage
Recent headlines mentioning XFOR from our newsroom.